Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Sep;85(7):1077–1083. doi: 10.1054/bjoc.2001.2027

Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants

V Pavillard 1, D Kherfellah 1, S Richard 1, J Robert 1, D Montaudon 1
PMCID: PMC2375103  PMID: 11592782

Abstract

From the rat C6 glioma cell line in culture, we selected camptothecin-resistant variants by growth in the presence of increasing amounts of this drug (C6CPT10, C6CPT50 and C6CPT100, growing respectively with 10, 50 and 100 ng ml–1camptothecin). The degree of resistance to camptothecin ranged between 15-fold (C6CPT10) and 30-fold (C6CPT50and C6CPT100). The C6CPT10cell line presented a collateral sensitivity to etoposide (3.6-fold), while the C6CPT50 and C6CPT100 cell lines were cross-resistant to etoposide (1.8-fold) The resistant lines were characterised by a two-fold reduced content and catalytic activity of topoisomerase I, and C6CPT50 and C6CPT100 presented a significant increase in topoisomerase IIα content and catalytic activity and a marked overexpression of P-glycoprotein. We explored the cytotoxicity of combinations of a topoisomerase I inhibitor (camptothecin) and a topoisomerase II inhibitor (doxorubicin or etoposide) at several molar ratios, allowing the evaluation of their synergistic or antagonistic effects on cell survival using the median effect principle. The simultaneous combination of camptothecin and doxorubicin or etoposide was additive or antagonistic in C6 cells, slightly synergistic in the C6CPT10 line and never more than additive in the C6CPT50 and C6CPT100 cell lines. The sequential combination of doxorubicin and camptothecin gave additivity in the order camptothecin → doxorubicin and antagonism in the order doxorubicin → camptothecin. Clinical protocols combining a topoisomerase I and a topoisomerase II inhibitor should be considered with caution because antagonistic effects have been observed with combinations of camptothecin and doxorubicin.© 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: topoisomerase inhibitors, drug combinations, camptothecin resistance

Full Text

The Full Text of this article is available as a PDF (86.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersen A. H., Svejstrup J. Q., Westergaard O. The DNA binding, cleavage, and religation reactions of eukaryotic topoisomerases I and II. Adv Pharmacol. 1994;29A:83–101. doi: 10.1016/s1054-3589(08)60541-4. [DOI] [PubMed] [Google Scholar]
  2. Ando M., Eguchi K., Shinkai T., Tamura T., Ohe Y., Yamamoto N., Kurata T., Kasai T., Ohmatsu H., Kubota K. Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer. Br J Cancer. 1997;76(11):1494–1499. doi: 10.1038/bjc.1997.584. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Andoh T., Okada K. Drug resistance mechanisms of topoisomerase I drugs. Adv Pharmacol. 1994;29B:93–103. doi: 10.1016/s1054-3589(08)61133-3. [DOI] [PubMed] [Google Scholar]
  4. Benda P., Lightbody J., Sato G., Levine L., Sweet W. Differentiated rat glial cell strain in tissue culture. Science. 1968 Jul 26;161(3839):370–371. doi: 10.1126/science.161.3839.370. [DOI] [PubMed] [Google Scholar]
  5. Bertrand R., O'Connor P. M., Kerrigan D., Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur J Cancer. 1992;28A(4-5):743–748. doi: 10.1016/0959-8049(92)90107-d. [DOI] [PubMed] [Google Scholar]
  6. Bonner J. A., Kozelsky T. F. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol. 1996;39(1-2):109–112. doi: 10.1007/s002800050545. [DOI] [PubMed] [Google Scholar]
  7. Chaudhary P. M., Roninson I. B. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993 Apr 21;85(8):632–639. doi: 10.1093/jnci/85.8.632. [DOI] [PubMed] [Google Scholar]
  8. Chen A. Y., Yu C., Potmesil M., Wall M. E., Wani M. C., Liu L. F. Camptothecin overcomes MDR1-mediated resistance in human KB carcinoma cells. Cancer Res. 1991 Nov 15;51(22):6039–6044. [PubMed] [Google Scholar]
  9. Chou T. C., Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4. [DOI] [PubMed] [Google Scholar]
  10. Endicott J. A., Ling V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 1989;58:137–171. doi: 10.1146/annurev.bi.58.070189.001033. [DOI] [PubMed] [Google Scholar]
  11. Herben V. M., ten Bokkel Huinink W. W., Dubbelman A. C., Mandjes I. A., Groot Y., van Gortel-van Zomeren D. M., Beijnen J. H. Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide. Br J Cancer. 1997;76(11):1500–1508. doi: 10.1038/bjc.1997.585. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hill B. T., Deuchars K., Hosking L. K., Ling V., Whelan R. D. Overexpression of P-glycoprotein in mammalian tumor cell lines after fractionated X irradiation in vitro. J Natl Cancer Inst. 1990 Apr 4;82(7):607–612. doi: 10.1093/jnci/82.7.607. [DOI] [PubMed] [Google Scholar]
  13. Huet S., Schott B., Robert J. P-glycoprotein overexpression cannot explain the complete doxorubicin-resistance phenotype in rat glioblastoma cell lines. Br J Cancer. 1992 Apr;65(4):538–544. doi: 10.1038/bjc.1992.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kaufmann S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res. 1991 Feb 15;51(4):1129–1136. [PubMed] [Google Scholar]
  15. Kohn K. W. Principles and practice of DNA filter elution. Pharmacol Ther. 1991;49(1-2):55–77. doi: 10.1016/0163-7258(91)90022-e. [DOI] [PubMed] [Google Scholar]
  16. Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
  17. Liu L. F. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem. 1989;58:351–375. doi: 10.1146/annurev.bi.58.070189.002031. [DOI] [PubMed] [Google Scholar]
  18. Liu L. F., Miller K. G. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc Natl Acad Sci U S A. 1981 Jun;78(6):3487–3491. doi: 10.1073/pnas.78.6.3487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Masumoto N., Nakano S., Esaki T., Tatsumoto T., Fujishima H., Baba E., Nakamura M., Niho Y. Sequence-dependent modulation of anticancer drug activities by 7-ethyl-10-hydroxycamptothecin in an HST-1 human squamous carcinoma cell line. Anticancer Res. 1995 Mar-Apr;15(2):405–409. [PubMed] [Google Scholar]
  20. Montaudon D., Pourquier P., Denois F., de Tinguy-Moreaud E., Lagarde P., Robert J. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells. Eur J Biochem. 1997 Apr 15;245(2):307–315. doi: 10.1111/j.1432-1033.1997.00307.x. [DOI] [PubMed] [Google Scholar]
  21. Nitiss J. L. Roles of DNA topoisomerases in chromosomal replication and segregation. Adv Pharmacol. 1994;29A:103–134. doi: 10.1016/s1054-3589(08)60542-6. [DOI] [PubMed] [Google Scholar]
  22. Oguro M., Seki Y., Okada K., Andoh T. Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed Pharmacother. 1990;44(4):209–216. doi: 10.1016/0753-3322(90)90026-6. [DOI] [PubMed] [Google Scholar]
  23. Osheroff N., Corbett A. H., Robinson M. J. Mechanism of action of topoisomerase II-targeted antineoplastic drugs. Adv Pharmacol. 1994;29B:105–126. doi: 10.1016/s1054-3589(08)61134-5. [DOI] [PubMed] [Google Scholar]
  24. Pommier Y., Tanizawa A., Kohn K. W. Mechanisms of topoisomerase I inhibition by anticancer drugs. Adv Pharmacol. 1994;29B:73–92. doi: 10.1016/s1054-3589(08)61132-1. [DOI] [PubMed] [Google Scholar]
  25. Rabier M. J., Bruno N. A., Slate D. L. Multifactorial resistance in LS174T human colon carcinoma cells selected with doxorubicin. Int J Cancer. 1991 Oct 21;49(4):601–607. doi: 10.1002/ijc.2910490423. [DOI] [PubMed] [Google Scholar]
  26. Robert J., Larsen A. K. Drug resistance to topoisomerase II inhibitors. Biochimie. 1998 Mar;80(3):247–254. doi: 10.1016/s0300-9084(98)80007-2. [DOI] [PubMed] [Google Scholar]
  27. Stahl M., Kasimir-Bauer S., Harstrick A. Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro. Anticancer Drugs. 1997 Aug;8(7):671–676. doi: 10.1097/00001813-199708000-00005. [DOI] [PubMed] [Google Scholar]
  28. Sugimoto Y., Tsukahara S., Oh-hara T., Liu L. F., Tsuruo T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res. 1990 Dec 15;50(24):7962–7965. [PubMed] [Google Scholar]
  29. Tan K. B., Mattern M. R., Eng W. K., McCabe F. L., Johnson R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst. 1989 Nov 15;81(22):1732–1735. doi: 10.1093/jnci/81.22.1732. [DOI] [PubMed] [Google Scholar]
  30. Wang J. C. DNA topoisomerases as targets of therapeutics: an overview. Adv Pharmacol. 1994;29A:1–19. doi: 10.1016/s1054-3589(08)60537-2. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES